Search Results

Business

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech plc announced its financial results for the second quarter of 2023 and provided an overview of the Company’s progress.

August 10, 2023

·

13 min read

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Vaccitech plc today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection.

September 13, 2023

·

5 min read

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its Phase 2 Hepatitis B trials of VTP-300.

November 6, 2023

·

8 min read

Business

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech plc (NASDAQ: VACC) (the Company, we or us) today announced its financial results for the first quarter of 2023 and an overview of the Company’s progress.

May 12, 2023

·

14 min read

Business

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Vaccitech plc today announced its financial results for year end 2022 and an overview of the Company’s progress.

March 24, 2023

·

18 min read

Publication in Cell Shows That Vaccitech’s SNAPvax™ Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel “Vax-Innate” Paradigm

Vaccitech plc announced the publication of research in preclinical animal models demonstrating the potential of Vaccitech’s SNAPvax for use in a novel paradigm for cancer treatment referred to as “VAX-INNATE.”

October 27, 2022

·

6 min read

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Vaccitech plc will present positive final data from the HBV002 clinical trial at the European Association for the Study of the Liver (EASL) Congress 2023.

June 21, 2023

·

10 min read

Business

Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer

Vaccitech plc today announced the appointment of Nadège Pelletier, Ph.D., as Chief Scientific Officer (CSO).

January 30, 2023

·

4 min read

Drug Development

Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions

Vaccitech plc today announced topline interim data from the HPV001 study (NCT04607850), a Phase 1b/2 clinical trial of VTP-200 in women with low-grade cervical human papillomavirus (HPV) lesions.

March 20, 2023

·

6 min read

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Vaccitech plc (NASDAQ: VACC) (the Company, we or us) today announced the dosing of the first patient in the PCA001 clinical trial (NCT05617040).

June 12, 2023

·

6 min read